The purpose of the Imaging Core is to support the in vivo imaging needs of the projects of the UCLA SPORE in Prostate Cancer. Non-invasive imaging is a key experimental approach for studying disease in intact organisms. The Imaging Core provides functional as well as anatomical imaging technologies to SPORE investigators, at the pre-clinical and clinical level. Furthermore, the Core works closely with investigators to develop and implement new imaging tracers and technologies. Finally, centralization of these services in a Core improves the quality and reliability of imaging-based data. The goals of the Imaging Core are : 1) to provide and support state-of-the-art small animal preclinical imaging research;2) to support innovative clinical imaging studies;and 3) to provide scientific and administrative support to Prostate SPORE investigators. Pre-clinical imaging studies are centralized in the Crump Institute imaging facility, which houses two microPET scanners, a microCT, three Xenogen IVIS optical imaging system, and a new Maestro multispectral fluorescence imager. Ancillary facilities including radiolabeling lab and rodent housing, are adjacent. In 2007 the preclinical Imaging Facility will relocate to new, spacious quarters in the California Nanosystems Institute building where it will continue to expand its offerings to investigators in oncologic molecular imaging. Clinical imaging and evaluation of novel radiolabeled tracers is supported by the Ahmanson Biological Imaging Clinic in the Geffen School of Medicine. Key aspects of the provision of imaging services are quality control and data acquision/storage/analysis, which the Imaging Core provides in order to ensure reliable access to the instrumentation and data. Lay description: One of the most exciting areas of medical research is the developing of new ways to """"""""see"""""""" what's going on, in pre-clinical models, and ultimately in patients. Molecular imaging will provide better ways to detect cancer, and smarter ways to understand its behavior and select the most effective therapy. The Imaging Core helps all SPORE investigators to integrate imaging into their basic investigations, and to develop new ways to detect prostate cancer in patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA092131-10
Application #
8291336
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
2013-06-30
Budget Start
2011-07-01
Budget End
2013-06-30
Support Year
10
Fiscal Year
2011
Total Cost
$94,066
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Cheng, Larry C; Li, Zhen; Graeber, Thomas G et al. (2018) Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer. J Vis Exp :
Park, Jung Wook; Lee, John K; Sheu, Katherine M et al. (2018) Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. Science 362:91-95
Tan, Nelly; Shen, Luyao; Khoshnoodi, Pooria et al. (2018) Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology. J Urol 199:1218-1223
Donin, Nicholas M; Reiter, Robert E (2018) Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer. J Nucl Med 59:177-182
Nagarajan, Mahesh B; Raman, Steven S; Lo, Pechin et al. (2018) Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate. Abdom Radiol (NY) 43:2487-2496
Calais, Jeremie; Fendler, Wolfgang P; Eiber, Matthias et al. (2018) Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med 59:434-441
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control 29:581-588
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 122:76-82
Jelinek, David; Flores, Aimee; Uebelhoer, Melanie et al. (2018) Mapping Metabolism: Monitoring Lactate Dehydrogenase Activity Directly in Tissue. J Vis Exp :
Lee, John K; Bangayan, Nathanael J; Chai, Timothy et al. (2018) Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A 115:E4473-E4482

Showing the most recent 10 out of 339 publications